University of Kentucky, Center for Biomedical Engineering, Lexington, Kentucky 40506-0070, USA.
J Biomed Opt. 2012 Jan;17(1):010901. doi: 10.1117/1.JBO.17.1.010901.
A novel near-infrared (NIR) diffuse correlation spectroscopy (DCS) for tumor blood flow measurement is introduced in this review paper. DCS measures speckle fluctuations of NIR diffuse light in tissue, which are sensitive to the motions of red blood cells. DCS offers several attractive new features for tumor blood flow measurement such as noninvasiveness, portability, high temporal resolution, and relatively large penetration depth. DCS technology has been utilized for continuous measurement of tumor blood flow before, during, and after cancer therapies. In those pilot investigations, DCS hemodynamic measurements add important new variables into the mix for differentiation of benign from malignant tumors and for prediction of treatment outcomes. It is envisaged that with more clinical applications in large patient populations, DCS might emerge as an important method of choice for bedside management of cancer therapy, and it will certainly provide important new information about cancer physiology that may be of use in diagnosis.
本文介绍了一种用于肿瘤血流测量的新型近红外（NIR）漫散射相关光谱（DCS）技术。DCS 测量组织中近红外漫散光的散斑波动，这些波动对红细胞的运动敏感。DCS 为肿瘤血流测量提供了几个有吸引力的新特性，如非侵入性、便携性、高时间分辨率和相对较大的穿透深度。DCS 技术已被用于癌症治疗前、治疗中和治疗后的肿瘤血流连续测量。在这些初步研究中，DCS 血流动力学测量为良性和恶性肿瘤的区分以及治疗效果的预测增加了重要的新变量。可以预见的是，随着在更大的患者群体中进行更多的临床应用，DCS 可能成为癌症治疗床边管理的重要选择方法，并且它肯定会提供有关癌症生理学的重要新信息，这些信息可能对诊断有用。
